Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 3 studies | 30% ± 5% | |
GABAergic neuron | 3 studies | 26% ± 1% | |
glutamatergic neuron | 3 studies | 35% ± 1% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 25% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1169.79 | 1445 / 1445 | 100% | 9.85 | 183 / 183 |
brain | 100% | 1319.91 | 2641 / 2642 | 100% | 13.12 | 705 / 705 |
breast | 100% | 769.26 | 459 / 459 | 100% | 9.58 | 1116 / 1118 |
bladder | 100% | 794.48 | 21 / 21 | 100% | 8.51 | 502 / 504 |
prostate | 100% | 750.12 | 244 / 245 | 100% | 9.36 | 502 / 502 |
uterus | 100% | 855.94 | 170 / 170 | 99% | 9.44 | 455 / 459 |
ovary | 100% | 737.89 | 180 / 180 | 99% | 6.87 | 426 / 430 |
lung | 99% | 627.90 | 573 / 578 | 100% | 8.88 | 1152 / 1155 |
thymus | 100% | 772.24 | 651 / 653 | 99% | 7.78 | 599 / 605 |
intestine | 100% | 656.08 | 964 / 966 | 99% | 8.70 | 521 / 527 |
stomach | 100% | 624.41 | 359 / 359 | 99% | 8.33 | 282 / 286 |
adrenal gland | 100% | 495.86 | 258 / 258 | 97% | 17.64 | 224 / 230 |
pancreas | 99% | 492.58 | 324 / 328 | 98% | 5.62 | 175 / 178 |
kidney | 100% | 591.17 | 89 / 89 | 96% | 6.92 | 869 / 901 |
liver | 100% | 574.35 | 226 / 226 | 96% | 4.64 | 391 / 406 |
skin | 100% | 1514.76 | 1809 / 1809 | 88% | 6.14 | 413 / 472 |
lymph node | 0% | 0 | 0 / 0 | 100% | 6.00 | 29 / 29 |
spleen | 100% | 520.46 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 11.16 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.26 | 1 / 1 |
blood vessel | 100% | 879.44 | 1333 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 722.01 | 1202 / 1204 | 0% | 0 | 0 / 0 |
muscle | 97% | 432.38 | 778 / 803 | 0% | 0 | 0 / 0 |
heart | 94% | 423.55 | 811 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 54% | 2.20 | 43 / 80 |
peripheral blood | 37% | 270.09 | 345 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0002244 | Biological process | hematopoietic progenitor cell differentiation |
GO_0018117 | Biological process | protein adenylylation |
GO_0042245 | Biological process | RNA repair |
GO_0000302 | Biological process | response to reactive oxygen species |
GO_0003972 | Molecular function | RNA ligase (ATP) activity |
GO_0005524 | Molecular function | ATP binding |
Gene name | RLIG1 |
Protein name | RNA ligase 1 (EC 6.5.1.3) (RNA ligase) (Rnl) Chromosome 12 open reading frame 29 |
Synonyms | C12orf29 hCG_27306 |
Description | FUNCTION: Functions as an RNA ligase, in vitro . The ligation reaction entails three nucleotidyl transfer steps . In the first step, the RNA ligase reacts with ATP in the absence of nucleic acid to form a covalent ligase-AMP intermediate and release pyrophosphate . In step 2, the ligase-AMP binds to the nucleic acid and transfers the adenylate to the 5'-PO4 terminus to form an adenylylated intermediate . In step 3, the RNA ligase directs the attack of the 3'-OH on the 5'-phosphoanhydride linkage, resulting in a repaired 3'-5' phosphodiester and release of AMP . Exhibits selectivity for single-stranded RNA substrates and may not have nick-sealing activity on double-stranded DNA-RNA hybrids . May play a role in maintaining RNA integrity under stress conditions, for example in response to reactive oxygen species (ROS) . . |
Accessions | ENST00000552121.5 [Q8N999-2] Q8N999 ENST00000356891.4 [Q8N999-1] ENST00000453037.7 [Q8N999-2] ENST00000552847.5 G3V1X7 ENST00000550333.5 [Q8N999-2] |